Prevention of Iron Deficiency Anemia Post-delivery
Key facts
- Who runs it
- NICHD Global Network for Women's and Children's Health
- Where
- Bangladesh, Congo - Kinshasa, Guatemala, India, Kenya, Pakistan, and Zambia8 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 4,857 people enrolled
- Started
- 30 May 2023
- Ended
- 28 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ferric carboxymaltose (FCM) and folic acid tablets
- Oral iron tablets and folic acid tablets
- Record updated
- 1 July 2026
Who can take part
- Age
- 15 years to 49 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Established pregnancy ≥28 weeks gestational age by last menstrual period and/or clinical assessment and/or ultrasonography
- Age: 18 years (or lower limit age eligible*) to 49 years
- Confirmed moderate anemia (Hb 7.0 to 9.9 g/dL, 6-48 hour after delivery based on a venous blood sample on Hemocue®)
- Deliver in participating study hospital or health facility
- Able to provide informed consent
- Plans to remain in study area for at least 6 months postpartum
Who cannot take part
- IV Iron infusion received in past 3 weeks
- Prior reaction to IV iron or oral iron or folic acid
- Blood transfusion already received or scheduled during the current hospital admission
- Major congenital anomaly prior to randomization
- Stillbirth or neonatal loss prior to randomization
- Positive malaria RDT prior to randomization (sub-Saharan African sites only)
- Contraindication to iron supplementation (some examples may include severe allergic states including asthma, hemolytic anemia, allergy, or severe infection)
- Known diagnosis of pre-existing depression or other psychiatric illness
- Known hemoglobinopathy (sickle cell disease or thalassemia)
- Any illness/condition requiring immediate medical care per physician's assessment
- Presenting with symptomatic anemia with dyspnea or fatigue and need for immediate correction
Where is this trial?
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
PRIORITY is designed as a 2-arm, randomized-controlled trial focused on postpartum women. The trial will recruit women who are diagnosed with moderate anemia based on a blood sample taken 6-48 hours after childbirth. A total of 4,800 eligible women, or 600 women per research site, will be consented and enrolled in the trial. The study hypothesizes that at 6 weeks postpartum, the incidence of achieving a non-anemic state (defined as Hb ≥11 g/dL) will be greater among women receiving a single-dose infusion of IV iron than among women receiving standard care with oral iron.
The 2 groups in the trial
- IV iron infusionTreatment being tested
Participants randomized to the IV iron arm will receive a single-dose infusion of IV FCM, to be initiated between 6-48 hours after delivery. All randomized participants will receive 400 mcg of folic acid daily for 6 months postpartum.
Treatment: Ferric carboxymaltose (FCM) and folic acid tablets
- Oral iron tabletsExisting treatment, for comparison
Participants randomized to the oral iron arm will receive 60 mg elemental iron twice daily. Treatment will be initiated between 6-48 hours after delivery and prior to discharge from the facility. After discharge, each participant will take a treatment dose of twice daily for 6 weeks postpartum. At 6 weeks postpartum, serum Hb will be assessed and participants with Hb \< 7.0 g/dL will stop treatment, participants with Hb 7.0-11.9 g/dL will continue taking 60 mg elemental iron twice daily and participants with Hb \> 11.9 g/dL will take 60 mg elemental iron once daily. All randomized participants will receive 400 mcg of folic acid daily for 6 months postpartum.
Treatment: Oral iron tablets and folic acid tablets
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research
- Record updated
- 1 July 2026